Journals / Medicine Science / 2022 / Cilt: 11 - Sayı: 2

New approaches in treatment of acute myeloid leukemia

Pages
914–919
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, new approaches and especially targeted agents in the treatment of AML are discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Historically acute myeloid leukemia (AML) treatment was limited to standard intensive induction chemotherapy with a combination of cytarabine and anthracycline for fit patients and non-intensive strategies with hypomethylating agent (HMA) or low dose cytarabine (LDAC).
📊
Key Findings & Data:Allogeneic stem cell transplantation has also become an important treatment option that prolongs survival in selected patients.
💡
Conclusion & Impact:In this article, new approaches and especially targeted agents in the treatment of AML are discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Historically acute myeloid leukemia (AML) treatment was limited to standard intensive induction chemotherapy with a combination of cytarabine and anthracycline for fit patients and non-intensive strategies with hypomethylating agent (HMA) or low dose cytarabine (LDAC). Allogeneic stem cell transplantation has also become an important treatment option that prolongs survival in selected patients. Over the last years with a better understanding of genomic and molecular pathogenesis of the disease, new treatment options have emerged with the contribution of translational studies. Especially less intensive frontline options have expanded. The combination of targeted therapies and standard therapies has helped to overcome treatment resistance and led to prolong survival. In this article, new approaches and especially targeted agents in the treatment of AML are discussed.

🔖

Cite This Article

KOCA, E. (2022). New approaches in treatment of acute myeloid leukemia. Medicine Science, Cilt: 11 - Sayı: 2, 914–919. https://ajindex.com/articles/579603

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Papaemmanuil E, Gerstung M, Bullinger M, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209- 21
  2. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-47
  3. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249-59
  4. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med.2009;361:1235-48
  5. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamycin. J Clin Oncol. 2009;27:504-10
  6. DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135;85-96
  7. Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14:49
  8. Kantajian HM, Kadia TM, DiNardo CD, et al. Acute myeloid leukemia treament and research outlook for 2021 and the MD Anderson approach. Cancer. 2021;86:1186-1207
  9. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trails. Cancer. 2006;107:116-24
  10. Burnett AK, Russel NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of medical research council AML15 trial. J Clin Oncol. 2013;31:3360-8
  11. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotehrapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903
  12. Candoni A, Papayannidis C, Martinelli G, et al. Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in CD33-positive AML: final results and long term outcome of a phase II multicenter clinical trial. Am J Hematol. 2018;93:655-63
  13. Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18:989-97
  14. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: a meta analysis of individual pateint data from randomised controlled trails. Lancet Oncol. 2014;15:986-96. 15.